Text představí ketaminem asistovanou psychoterapii (KAP) jako novou léčebnou modalitu v psychiatrii pro široké diagnostické spektrum. Tato metoda má odlišné charakteristiky i indikace od použití esketaminu či racemického ketaminu v off-label use u deprese. Je unikátní kombinací farmakologického i psychoterapeutického přístupu tím, že aktivně využívá změněný stav vědomí vyvolaný ketaminem k zásadní akceleraci a prohloubení psychoterapeutického procesu. Podkladem této akcelerace je indukce neuroplastického procesu, zvýšená schopnost učení, a tím pádem efektivnější psychoterapie. Metoda částečně navazuje jednak na objev rychlého antidepresivního a anxiolytického účinku ketaminu z přelomu tisíciletí, jednak na metodiku psychedelické psychoterapie 50. a 60. let 20. století. V současné době se rychle rozvíjí především v USA; v ČR implementuje tento model do zdravotní péče Psyon – Psychedelická klinika, ale v poslední době vznikají i další takto specializovaná pracoviště. Text je krátkým přehledem využití ketaminu v psychiatrii a souhrnem dosavadního výzkumu o použití ketaminu v psychoterapii, představí východiska KAP a odliší KAP od jiných přístupů práce s ketaminem.
The text introduces Ketamine-Assisted Psychotherapy (KAP) as a new therapeutic modality in psychiatry for a broad diagnostic range. This method has distinct characteristics and indications compared to the use of esketamine or racemic ketamine off-label for depression. KAP uniquely combines pharmacological and psychotherapeutic approaches by actively utilizing the altered state of consciousness induced by ketamine to significantly accelerate and deepen the psychotherapeutic process. The foundation of this acceleration lies in the induction of neuroplastic processes, enhanced learning capacity, and thereby more effective psychotherapy. The method partially builds on the discovery of ketamine's rapid antidepressant and anxiolytic effects from the turn of the millennium, as well as on the methodology of psychedelic psychotherapy from the 1950s and 1960s. Currently, it is rapidly developing, especially in the United States. In the Czech Republic, this model is being implemented into healthcare by Psyon – Psychedelic Clinic, and recently, other specialized centers have also emerged. The text is a brief overview of the use of ketamine in psychiatry and a summary of the current research on the application of ketamine in psychotherapy. It introduces the principles of KAP and distinguishes KAP from other approaches to working with ketamine.
- MeSH
- deprese farmakoterapie terapie MeSH
- duševní poruchy farmakoterapie klasifikace terapie MeSH
- halucinogeny farmakologie terapeutické užití MeSH
- ketamin * farmakologie terapeutické užití MeSH
- kombinovaná terapie metody MeSH
- lidé MeSH
- obsedantně kompulzivní porucha farmakoterapie terapie MeSH
- poruchy příjmu potravy farmakoterapie terapie MeSH
- psychoterapie * metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- přehledy MeSH
The growing interest in and prevalence of the use of psychedelics, as well as the potential benefits and negative consequences associated with psychedelic experiences, create a need for mental health specialists to be able to provide adequate and effective intervention regarding the content and consequences of these experiences, that is, psychedelic integration. At the same time, current graduate training in psychiatry, psychology, psychotherapy, counseling, etc., fails to adequately prepare professionals for such interventions. In order to fill this gap, an international, bottom-up project was established to attempt developing guidelines. This project was conducted by means of literature reviews as well as roundtable discussions among project participants, leading to a consensus on the guidelines' final scope and content. Drawing from the outcomes of this project, this article presents proposed comprehensive guidelines covering both theoretical and practical aspects of psychedelic integration, that are intended to serve as a resource for various mental health specialists who may encounter individuals in need of support considering their psychedelic experiences. These guidelines encompass clinician-friendly information on the effects of psychedelics, a definition of psychedelic integration, the general theoretical considerations linked to utilization of psychedelic experiences in clinical practice, a simple model organizing the course of psychedelic integration practice, as well as an overview of the current models of psychedelic integration, along with a selective presentation of basic and specific interventions derived from various psychotherapeutic approaches that can be employed in the practice of psychedelic integration.
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
INTRODUCTION: Psilocybin is one of the most extensively studied psychedelic drugs with a broad therapeutic potential. Despite the fact that its psychoactivity is mainly attributed to the agonism at 5-HT2A receptors, it has high binding affinity also to 5-HT2C and 5-HT1A receptors and indirectly modulates the dopaminergic system. Psilocybin and its active metabolite psilocin, as well as other serotonergic psychedelics, induce broadband desynchronization and disconnection in EEG in humans as well as in animals. The contribution of serotonergic and dopaminergic mechanisms underlying these changes is not clear. The present study thus aims to elucidate the pharmacological mechanisms underlying psilocin-induced broadband desynchronization and disconnection in an animal model. METHODS: Selective antagonists of serotonin receptors (5-HT1A WAY100635, 5-HT2A MDL100907, 5-HT2C SB242084) and antipsychotics haloperidol, a D2 antagonist, and clozapine, a mixed D2 and 5-HT receptor antagonist, were used in order to clarify the underlying pharmacology. RESULTS: Psilocin-induced broadband decrease in the mean absolute EEG power was normalized by all antagonists and antipsychotics used within the frequency range 1-25 Hz; however, decreases in 25-40 Hz were influenced only by clozapine. Psilocin-induced decrease in global functional connectivity and, specifically, fronto-temporal disconnection were reversed by the 5-HT2A antagonist while other drugs had no effect. DISCUSSION: These findings suggest the involvement of all three serotonergic receptors studied as well as the role of dopaminergic mechanisms in power spectra/current density with only the 5-HT2A receptor being effective in both studied metrics. This opens an important discussion on the role of other than 5-HT2A-dependent mechanisms underlying the neurobiology of psychedelics.
- Publikační typ
- časopisecké články MeSH
Psilocybin is investigated as a fast-acting antidepressant used in conjunction with psychotherapy. Intact cognitive functions, including memory, are one of the basic conditions of effective psychedelic-assisted therapy. While cognitive and memory processing is attenuated on various domains during psilocybin intoxication, the effect of psilocybin on the consolidation of memories learned outside of acute intoxication is not known. Thus the main aim of the current study was to test the effects of psilocybin on (A) memory consolidation of previously learned material just after the psilocybin session and (B) on overnight memory consolidation the night just after the psilocybin session. 20 healthy volunteers (10 M/10F) were enrolled in a placebo-controlled, double-blind, cross-over design. Effects on declarative memory consolidation in condition (A) The Groton Maze Learning Task and Rey Auditory Verbal Learning Test were used, and for (B) the Pair Associative Learning Test was used. We did not find psilocybin to improve memory consolidation. At the same time, we did not find psilocybin to negatively affect memory consolidation in any of the tests used. This evidence adds to the safety profile for the use of psilocybin.
